Understanding the neurobiology of sleep and its benefits on health and wellness continues to evolve, and new strategies have emerged to treat individuals with sleep disorders. Sleep medicine is poised to deliver care in a precision medicine model. For example, some sleep centers are using pharmacogenomics to identify better fits for medication use for patients with sleep disorders to maximize benefits and minimize potential adverse effects. New tools help nonsleep specialists identify patients with potential sleep disordersand some generate referrals, implement behavioral modifications (eg, patient homework), and provide customized education, including outlining next steps and risks of not being evaluated and treated (Figure 1).1 Every year, new options emerge to better evaluate and treat patients with sleep disorders. Many devices and treatment options are in early-stage development, and others are in clinical trials or available.
Figure 1. Screenshots from MySleepApp show how digital screening can help identify and advise patients about potential sleep disorders.
Chronic insomnia is generally categorized as difficulty falling asleep or maintaining a regular sleep schedule for at least 3 months.2 Patients often experience daytime sleepiness and/or reduced cognitive function that negatively interferes with daily life, affecting productivity and mood. Insomnia remains a clinical diagnosis based on these symptoms and does not require polysomnography. Clinicians, however, now have Food and Drug Administration (FDA)-approved home monitoring devices to help evaluate insomnia, which can provide high-value care for patients and more individualized understanding of a particular patient’s sleep patterns.
The accepted standard treatment for chronic insomnia is cognitive-behavioral therapy for insomnia (CBT-I). In CBT-I, patients are guided through a structured and personalized program, typically by a sleep behavior psychologist, to modify their cognitive processes and sleep behaviors in an effort to improve their sleep. The American Academy of Sleep Medicine and the American College of Physicians recommend CBT-I as first-line treatment for chronic insomnia.3 Strategies for CBT-I management options are listed in the Table.4-7 Because of the limited number of fellowship-trained sleep psychologists, alternative options (eg, supervised behavioral sleep-trained nurses, individuals with a master’s degree in psychology, or wellness coaches) are being explored. If patients can not access in-person CBT-I, it can be offered online or via video conference.8
Other adjunctive techniques may also help treat insomnia. Mindfulness meditation can help patients adopt new ways to manage symptoms through meditation exercises, discussions, and daily monitoring of sleep-wake activities. A study showed that sleep efficacy improved from 30.87% to 69.87% following mindfulness meditation alone; however, this study was limited by lack of a control group. A randomized controlled trial is currently being performed to seek more evidence for efficacy of mindfulness meditation.9,10 Acupuncture, either alone or in combination with other treatments is an option. Acupuncture combined with estazolam (a sedative/hypnotic benzodiazepine) led to higher rates of improving sleep initiation, duration, and efficiency compared with estazolam alone.11 Although acupuncture may be effective, larger trials are still needed to assess the long-term effects.12 Hypnotherapy may have benefit, but there are some precautions to consider (eg, headache, drowsiness, creation of false memories, or strong emotions due to stressful events from earlier memories).13
Sleep-Promoting Devices and Tools
A number of devices hold promise for insomnia resolution. Cranial electrical stimulation (CES) is increasingly being considered, but more research is needed to assess its clinical benefits. Alpha stimulation is a type of CES that is an FDA-approved, handheld, prescription medical device.14 Transcranial magnetic stimulation (TMS) has been used to understand the neurobiology of insomnia and proposed as a potential therapeutic tool.15 Currently, TMS is primarily used to alleviate symptoms of depression, anxiety, and migraine. Previous work has shown that TMS is safe and effective. Some studies of TMS have reported significant improvements in sleep quality, suggesting it may also be an option in the future. Open-loop audio-visual stimulation (AVS), an at-home biofeedback program using light and sound patterns to induce slow brainwaves, is being investigated as treatment for insomnia.16
Medications to treat insomnia are not always warranted or recommended, but there are times when they can be considered. Hypocretin antagonists are relatively new treatments for insomnia. (See Sleep, Sleeplessness, and Neuropsychiatric Conditions in this issue). With a move toward precision medicine, clinicians are able to personalize health care to each patient’s unique variables that trigger and subsequently mitigate their insomnia symptoms. For example, individuals suffering from insomnia due to post-traumatic stress disorder or substance-use disorder may respond better to certain approaches compared with others.17,18 Pharmacogenomics is being used for patients with insomnia when medications are indicated, allowing for identification of a better medication match for the patient. In some instances, evidence for the lack of a good medication fit facilitates engagement in CBT–I.
From a clinical perspective, sleep specialists may recommend other commercially available sleep tools (eg, white-noise devices, light therapy, blue/green-light–blocking glasses, or special blankets, mattresses, or pillows). Weighted blankets, which have been found to increase sleep time and provide more secure sleep, may be of benefit for patients with insomnia but have not been subjected to any rigorous study. Despite the lack of an evidence base, clinical experience has demonstrated that cooling mattresses, pillows, and blankets may also provide some benefit for insomnia, particularly in patients with neurologic disorders (eg, multiple sclerosis) who have heat sensitivity or in postmenopausal women who experience flushing during the night. Although efficacy data are limited, sleep specialists are bringing such tools into their armamentarium to provide comfort and more personalized care for patients. Technology companies have also been developing consumer devices aimed at improving sleep quality (eg, Ebb Insomnia Therapy headband, Dreem Headband, SomniResonance SR1 sleep device, Dodow Sleep, and URGONight), but further study is required to assess their place in clinical practice.
Circadian Rhythm Sleep-Wake Disorders
In individuals with circadian rhythm sleep-wake disorders (CRSWD), the sleep-wake rhythm is disrupted by internal (eg, genetic predispositions or comorbid conditions) or external factors (eg, increased exposure to bright light, night-work schedule, or personal life difficulties).19 Typically, patients with CRSWD experience insomnia or excessive sleepiness but can have both depending upon the nature of their circadian misalignment. Diagnosing CRSWD requires identifing irregular sleep-wake patterns based on a patient’s sleep log. Common CRSWD include delayed sleep-wake phase disorder, advanced sleep-wake phase disorder, irregular sleep-wake disorder, shift-work disorder, and jet lag. Actigraphy, in which the patient wears a device to measures nighttime movements to indirectly measure sleep through inactivity, may be used in the evaluation by detecting an irregular sleep-wake cycle.20
In addition to CBT-I, medications may be used to help manage CRSWD. Melatonin is commonly used as a circadian rhythm anchor; however, the recommended dosages and timing remain unstandardized. Chronotherapy (gradually shifting the sleep time in accordance with a desired schedule) and bright light therapy can also be used to reset the sleep-wake rhythm and help alleviate insomnia or hypersomnia. Increased or decreased exposure to bright light at a particular time can significantly stabilize the circadian rhythm, thus improving sleep and mood. Physical exercise may also be beneficial. Exercise increases the core body temperature, reduces anxiety, promotes serotonin release, and modifies immune function, all of which may benefit sleep initiation. Exercise at different times of the 24-hour day has been shown to result in phase advances that are specific to the time of exercise, and, thus, can be strategically used to gradually shift the circadian rhythm to be parallel with the desired cycle, resulting in improved sleep quality. Whereas late nocturnal exercise can delay circadian timing, exercise in the early evening can advance the intrinsic biorhythm.21 It is important to speak with patients regarding their exercise routines and work with them to identify optimal exercise times that will not interfere with their sleep and may even improve sleep quality.
Among the most common sleep-related breathing disorders, obstructive sleep apnea (OSA) affects patients of all ages. Patients with morbid obesity, type 2 diabetes, epilepsy, or cardiovascular disease are at higher risk for OSA, which occurs when upper airway obstruction leads to repetitive episodes of apnea or hypopnea during sleep. Typically associated with heart failure or neurologic disease, central sleep apnea (CSA) is less common, occuring when the central neural signal to breathe is not transmitted. Patients with OSA or CSA experience difficulty breathing during sleep, insomnia, daytime fatigue or sleepiness, and/or snoring. Sleep apnea is associated with several risks (eg, cardiac disease, stroke, hypertension, diabetes, reflux, erectile dysfunction, weight gain, memory and concentration issues, and mood disturbances) and can be listed as a cause of death on death certificates.
Continuous positive airway pressure (CPAP) therapy remains the first-line therapy, especially in moderate or severe OSA. Positive airway pressure is used to maintain airway patency. There are challenges with adherence to CPAP because some patients may have claustrophobia or anxiety and can experience difficulty tolerating the mask or treatment pressures. Optimizing mask comfort in a single session by refitting a patient's mask can result in improved adherence and thus represents a simple and cost-effective approach to improving outcomes.22 Personalized 3D-printed CPAP masks may be a new potential method to treat patients with OSA because they could improve comfort and effectiveness in a more personalized manner. Although available for children with OSA and craniofacial anomalies, these 3D-printed CPAP masks for adults with OSA are not yet available clinically.23
Oral dental appliances are approved therapy for mild and mild-to-moderate OSA. The oral appliance pushes the lower jaw and tongue slightly forward, preventing throat muscles from collapsing back into the airway and allowing for normal breathing during sleep. Positional therapy may be an option for patients with positional OSA, particularly given the efficacy of a new generation of objective monitoring/stimulating devices, which may improve upon the limited efficacy of prior methods (such as the “tennis ball method” or any variety of positioning devices that can be strapped on).24,25
Although surgical intervention is not first-line treatment for OSA, patients may benefit from a formal evaluation based on their specific combination of anatomic risk factors. The recent approval of hypoglossal nerve stimulators that activate upper airway breathing) may be another option, particularly for individuals with moderate-to-severe OSA who fail CPAP therapy.26 An implantable neurostimulation device may be another new treatment method for CSA in patients with comorbid heart failure but long-term use, safety, tolerability, efficacy, and battery shelf life are currently under clinical investigation.27,28
Although there are no approved medications for OSA, cannabinoids have gained attention. Dronabinol has been shown effective for patients with moderate or severe OSA based on a blinded parallel, placebo-controlled, randomized trial. Specifically, dronabinol was associated with lower apnea-hypopnea index (AHI) and overall treatment satisfaction compared with placebo. The best approach to cannabinoid therapy for OSA remains unclear; large trials are needed to assess treatment approaches.29 Dimethyl fumarate, an immunomodulatory agent approved for treatment of multiple sclerosis is being studied as a potential treatment of OSA.30
Central hypersomnias, including idiopathic hypersomnia (IH) and narcolepsy, result in profound hypersomnia or excessive daytime sleepiness.31 Narcolepsy, often un- or under-diagnosed, can affect almost all aspects of life with sudden episodes of hypersomnolence. Type 1 narcolepsy is the combination of hypersomnia and either cataplexy— sudden loss of muscle tone triggered by strong emotions—or a deficiency of hypocretin (orexin), a chemical that promotes wakefulness, arousal, and appetite. Type 2 narcolepsy does not include cataplexy or a hypocretin deficiency.
Sodium oxybate is the first-line and only approved treatment for cataplexy32,33 and was recently approved for pediatric patients with narcolepsy. Tricyclic antidepressants (TCAs) have been used to treat cataplexy, despite not being thoroughly evaluated in randomized controlled trials and having undesirable anticholinergic effects. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) are another option to treat cataplexy, with venlafaxine being the preferred choice. Additionally, TCAs, SSRIs, and SNRIs may help with other symptoms common in narcolepsy: sleep paralysis and hypnagogic/hypnopompic hallucinations. Pitolisant, an inverse agonist of the H3 histamine receptor, is the newest medication, hoped to be approved soon for narcolepsy, targeting cataplexy and excessive daytime sleepiness.34
Modafinil, a nonamphetamine, wakefulness-promoting agent, is used to treate excessive daytime sleepiness in narcolepsy, followed by various other stimulant medications. There are a host of additional therapies being developed to address the excessive daytime sleepiness of the primary central nervous system hypersomnias. The H3 histamine receptor inverse agonists and a novel dopamine-norepinephrine reuptake inhibitor, solriamfetol, have both demonstrated efficacy for excessive daytime sleepiness associated with narcolepsy and other primary and secondary hypersomnias, but are not yet approved.34-36 Other drugs under investigation for hypersomnia include hypocretin/orexin peptides, cell replacement therapies, GABAB agonist baclofen, and immunomodulation..37
There are no approved medications for treatment of IH. Modafinil, various stimulants (eg, methylphenidate), and sodium oxybate are generally used off-label for hypersomnia in IH. Other treatments such as BTD-001, a GABAA antagonist, are currently in development.38 Finally, referral to the sleep behavioral psychologist can also be helpful in improving behaviors and practices for better sleep quality.
Rapid-Eye-Movement Sleep Behavior Disorder
Involving loss of atonia associated with rapid-eye-movement (REM) sleep, REM sleep behavior disorder (RBD) causes physical dream enactment that can result in harm to the patient or bed partner. Securing the sleep environment for safety and optimizing sleep practices are key. Relaxation techniques and the use of weighted blankets, sleeping bags, or bed/door alarms, can also help. Imaging rescripting (IR) and imaginal exposure (IE) as part of CBT can also be helpful. In IR, an individual suffering from nightmares identifies the negative beliefs and memories in order to change those into meaningful, positive experiences. In IE, patients are encouraged to imagine the feared images, thoughts, or situations and repetitively confront those until their nightmares are no longer frightening.39 Melatonin and clonazepam are the common medications used to treat RBD, but their efficacy and safety are limited. Although only a small body of literature exists to support its use in RBD, clonazepam is noted to be more than 80% efficacious.40 However, because of the multiple risks of using benzodiazepines in individuals over age 65, melatonin may be a better first choice. As a result of the limited options for treating this potentially devastating disorder, studies are underway to explore other medications that may help prevent RBD episodes, based on case reports in patients with RBD refractory to current therapies.41-43
Restless Legs Syndrome
Characterized by a strong, irresistible urge to move the limbs, restless legs syndrome (RLS) is diagnosed when this urge gets worse during rest or periods of inactivity. Patients often find sensations in their legs uncomfortable and describe them as aching, pulling, itching, crawling, or creeping.44 The neurobiology of RLS remains complex (Figure 2). It is theorized that iron deficiency leads to downregulation of adenosine A1 receptors (A1R) that cause hypersensitive striatal glutamatergic terminals and an increase in striatal dopamine release. The increased dopaminergic and glutamatergic activity gives rise to the commonly associated phenomenon of periodic limb movements of sleep (PLMS) as well as hyperarousal.45)>
Figure 2. The neurobiology of restless leg syndrome (RLS). A1R, adenosine 1 receptor. Courtesy of Julia Duvall and Tyler Pugeda, Baltimore, MD.
Iron therapy is a mainstay of treatment for patients with RLS who have low iron; iron status should always be part of the evaluation in RLS.46 Subsequently, α2δ ligands (eg, gabapentin, enacarbil, or pregabalin) are preferred first-line agents over dopaminergic therapy because of their short-term efficacy with the lower risk of augmentation of RLS.47 Nonetheless, the non-ergoline dopamine agonists, such as pramipexole, ropinirole, and rotigotine, often used in standard RLS treatment might be helpful for personalizing treatment in patients with RLS and comorbid Parkinson’s disease. Moreover, although age has not been shown to effect ropinirole and rotigotine metabolism, pramipexole plasma concentration can be as much as 68% higher in indviduals over age 65 compared to those under age 65 when given the same dose. Patients who are more than age 65 may require about one-third the daily dose of pramipexole to achieve the same plasma concentration as individuals less than age 65.48
Finally, although low-dose opioid therapy is a viable practice-parameter–approved option for patients with RLS, both patients and clinicians face the challenges of using opioids or any narcotic in the current opioid-abuse epidemic. Opioids can also exacerbate sleep problems, such as sleep apnea. Other strategies should be tried before considering opioids.49
Long-term treatment of RLS can be challenging and pharmacogenomics may be helpful. The development of new drugs acting on adenosinergic (including recent report of the use of dipyridamole) and glutamatergic neurotransmission hold promise, but require further investigation.50 As the genetic underpinnings and central and peripheral pathophysiology of this disorder are being revealed, more targeted therapies can be developed to address the specific mechanism of disease.
Several new and promising avenues to treat sleep disorders have arisen in recent years. Time will tell which of several novel agents currently at various stages of clinical trials are safe and effective. Longitudinal outcome studies are required for newly approved management options to assess their long-term safety and efficacy. Regardless, the outlook is promising that providers will have a greater armamentarium of treatment options as we are just beginning to reveal and target the underlying mechanisms of sleep and wake.
1. Doshi A, Gamaldo CE, Dziedzic P, et al. Finding time for sleep: identifying sleep concerns in non-sleep specialty clinics using the MySleepScript App. J Mobile Tech Med. 2017;6:2:19-27.
2. Edinger J, Buysee D, Lichstein K, Mindell J, Morin C. Insomnia. In: Sateia M, ed. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014: 19-46.
3. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125-133.
4. Saddichha S. Diagnosis and treatment of chronic insomnia. Ann Indian Acad Neurol. 2010;13(2):94-102.
5. Johns Hopkins Medicine. Preparing your bedroom for a great night’s sleep. Johns Hopkins Medicine website. https://www.hopkinsmedicine.org/health/healthy-sleep/sleep-better/preparing-your-bedroom-for-a-great-nights-sleep. Accessed February 9, 2019.
6. Johns Hopkins Medicine. Sleepless nights? Try stress relief techniques. Johns Hopkins Medicine website. https://www.hopkinsmedicine.org/health/healthy-sleep/sleep-better/sleepless-nights-try-stress-relief-techniques. Accessed February 9, 2019.
7. Levendowski DJ, Ferini-Strambi L, Gamaldo C, et al. The accuracy, night-to-night variability, and stability of frontopolar sleep electroencephalography biomarkers. J Clin Sleep Med. 2017;13(6):791-803.
8. McCarthy MS, Matthews EE. Effects of an internet-based videoconference cognitive behavioral therapy for insomnia intervention. Sleep. 2017;40(S1):A141.
9. Ong J, Sholtes D. A mindfulness-based approach to the treatment of insomnia. J Clin Psychol. 2010;66(11):1175-1184.
10. Rusch HL, Rosario M, Levison LM, et al. The effect of mindfulness meditation on sleep quality: a systematic review and meta-analysis of randomized controlled trials. Ann N Y Acad Sci. 2018. doi:10.1111/nyas.13996.
11. Ding L, Wang J, Yang H, Yu J. [“Governor vessel daoqi method of acupuncture” combined with estazolam for insomnia: a randomized controlled trial]. Zhongguo Zhen Jiu. 2018;38(5): 4633-4637.
12. Cao H, Pan X, Li H, Liu J. Acupuncture for treatment of insomnia: a systematic review of randomized controlled trials. J Altern Complement Med. 2009;15(11):1171-1186.
13. Lam TH, Chung KF, Lee CT, Yeung WF, Yu BY. Hypnotherapy for insomnia: a randomized controlled trial comparing generic and disease-specific suggestions. Complement Ther Med. 2018;41:231-239.
14. Shekelle PG, Cook IA, Miake-Lye IM, et al. Benefits and harms of cranial electrical stimulation for chronic painful conditions, depression, anxiety, and insomnia: a systematic review. Ann Intern Med. 2018;168(6):414-421.
15.Salas R, Galea J, Gamaldo A, et al. Increased use-dependent plasticity in chronic insomnia. Sleep. 2014; 37(3): 535-544.
16. Tang HY, Riegel B, McCurry SM, Vitiello MV. Open-loop audio-visual stimulation (AVS): a useful tool for management of insomnia? Appl Psychophysiol Biofeedback. 2016;41(1):39-46.
17. Hendrickson RC, Raskind MA, Millard SP, et al. Evidence for altered brain reactivity to norepinephrine in veterans with a history of traumatic stress. Neurobiol Stress. 2018;8:103-111.
18. Bramoweth A, Luther J, Hanusa B, et al. Clinical characterization of insomnia among veterans with PTSD: identifying risk factors for diagnosis and treatment with sedative-hypnotics. Defence Peace Econ. 2018;29(1):78-90.
19. Zee P, Owens J, Auger R, et al. Circadian rhythm sleep-wake disorders. In: Sateia M, ed. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014:189-224.
20. Smith MT, McCrae CS, Cheung J, et al. Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE Assessment. J Clin Sleep Med. 2018;14(7):1209-1230.
21. Buxton OM, Lee CW, L’Hermite-Baleriaux M, Turek FW, Van Cauter E. Exercise elicits phase shifts and acute alterations of melatonin that vary with circadian phase. Am J Physiol Regul Integr Comp Physiol. 2003;284(3):R714-24.
22. Kandel SP, Shalom IH, Kitzen O, Ahmed Q, Weinstein MD. Early intervention with single session “mask-fitting” improves CPAP adherence in obstructive sleep apnea syndrome patients. Am J Resp Crit Care Med. 2018;197:A1495.
23. Aufieri R, Picone S, Gente M, Paolillo P. 3D printing in neonatal care. Ital J Pediatr. 2015;41(Suppl 1): A1.
24. Ravesloot MJL, White D, Heinzer R, Oksenberg A, Pepin JL. Efficacy of the new generation of devices for positional therapy for patients with positional obstructive sleep apnea: a systematic review of the literature and meta-analysis. J Clin Sleep Med. 2017;13(6):813-824.
25. Ravesloot MJL, Maanen JPV, Dun L, de Vries N. The undervalued potential of positional therapy in position-dependent snoring and obstructive sleep apnea–a review of the literature. Sleep Breath. 2013;17(1):39-49.
26. Wray CM, Thaler ER. Hypoglossal nerve stimulation for obstructive sleep apnea: a review of the literature. World J Otorhinolaryngol Head Neck Surg. 2016;2(4):230-233.
27. Poinkowski P, Javaheri S, Michalkiewicz D, et al. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J. 2012;33:889-894.
28. Fox H, Bitter T, Horstkotte D, Oldenburg O, Gutleben KJ. Long-term experience with first-generation implantable neurostimulation device in central sleep apnea treatment. Pacing Clin Electrophysiol. 2017;40(5):498-503.
29. Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep. 2018;41(1). doi: 10.1093/sleep/zsx184.
30. Braley TJ, Huber AK, Segal BM, et al. A randomized, subject and rater-blinded, placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea. Sleep. 2018;41(8). doi: 10.1093/sleep/zsy10.9
31. Central disorders of hypersomnolence. In: Sateia M, ed. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014:146-163.
32. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-1711.
33. Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13(10):1035-1048.
34. Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200-207.
35. Rouff C, Bogan RK, Emsellem H, et al. Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the maintenance of wakefulness test censored to 20 minutes. Sleep Med. 2017;35:12-16.
36. Swick T. Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep. 2015;7:159-169.
37. Evangelista E, Lopez R, Dauvilliers Y. Update on treatment for idiopathic hypersomnia. Expert Opin Investig Drugs. 2018;27(2):187-192.
38. Kunze A, Lancee J, Morina N, Kindt M, Arntz A. Efficacy and mechanisms of imagery rescripting and imaginal exposure for nightmares: study protocol for a randomized controlled trial. Trials. 2016;17:469.
39. Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85-95.
40. Moghadam KK, Pizza F, Primavera A, Ferri R, Plazzi G. Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. Sleep Med. 2017;32:16-21.
41. Shneerson JM. Successful treatment of REM sleep behavior disorder with sodium oxybate. Clin Neuropharmacol. 2009;32(3):158-159.
42. Liebenthal J, Valerio J, Ruoff C. A case of rapid eye movement sleep behavior disorder in Parkinson’s disease treated with sodium oxybate. JAMA Neurol. 2016;73(1):126-127.
43. Bornemann MC, Schenck C, Rosen G, Pressman M Sleep related movement disorders. In: Sateia M, ed. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014: 228-279.
44. Ferre S, Quiroz C, Guitart X, et al. Pivotal role of adenosine neurotransmission in restless legs syndrome. Front Neurosci. 2018;11:722.
45. Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med. 2018;41:27-44.
46. Salminen AV, Winkelmann J. Restless legs syndrome and other movement disorders of sleep-treatment update. Curr Treat Options Neurol. 2018;20(12):55.
47. Contin M, Lopane G, Mohamed S, et al. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2018;S1353-8020(18)30488-30487.
48. Silber MH, Becker PM, Buchfuhrer MJ, et al. The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc. 2018;93(1):59-67.
49. Garcia-Borreguero D, Guitart X, Garcia Malo C, et al. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med. 2018;45:94-97.
50. Zucconi M, Galbitati A, Rinalidi F, Casoni F, Ferini-Strambi L. An update on the treatment of restless legs syndrome/Willis-Ekbom disease: prospects and challenges. Expert Rev Neurother. 2018;18(9):705-713.
The authors have no financial or other relationships relevant to this content to disclose.